- Home
- ALXO vs XBP Comparison
ALXO vs XBP Comparison
Compare ALXO & XBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALXO | XBP |
|---|---|---|
| Founded | 2015 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.7M | 81.7M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALXO | XBP |
|---|---|---|
| Price | $1.33 | $6.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $3.30 | N/A |
| AVG Volume (30 Days) | ★ 177.3K | 34.0K |
| Earning Date | 11-07-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,823,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.40 | $4.11 |
| 52 Week High | $2.27 | $25.60 |
Technical Indicators
Market Signals| Indicator | ALXO | XBP |
|---|---|---|
| Relative Strength Index (RSI) | 42.54 | 82.90 |
| Support Level | $1.37 | $5.12 |
| Resistance Level | $1.53 | $7.01 |
| Average True Range (ATR) | 0.11 | 0.45 |
| MACD | -0.01 | 0.42 |
| Stochastic Oscillator | 12.12 | 91.52 |
Price Performance
Historical ComparisonAbout ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About XBP XBP Europe Holdings Inc.
XBP Global Holdings Inc is a multinational leader in business process automation, serving over 2,500 clients-including more than 30 Fortune 100 companies. Its proprietary software and deep domain expertise position it as a trusted technology and services partner. With cloud-based solutions and a global footprint, XBP Global delivers measurable value, improves advances digital transformation, improves market-wide liquidity by expediting payments, and promotes sustainable business practices.